Summary
Pfizer Inc.'s 10-Q filing for the period ending March 30, 1996, indicates a company in a period of reporting and operational activity. While the provided text is a directory listing of the filing rather than the detailed financial statements, it confirms the filing date and period. Investors interested in Pfizer during this time would look for information on sales performance, new drug development, clinical trial progress, and any significant acquisitions or divestitures. The absence of specific financial figures in this excerpt means a deeper dive into the actual 10-Q document would be necessary to assess the company's financial health and future prospects.
Key Highlights
- 1Pfizer Inc. filed its quarterly report (10-Q) for the period ending March 30, 1996, on May 13, 1996.
- 2The filing confirms Pfizer was actively reporting to the SEC as of this date.
- 3This report provides a snapshot of the company's financial and operational status during the first quarter of 1996.
- 4Investors would typically use such filings to evaluate revenue, profitability, and strategic initiatives.
- 5The presence of detailed filings implies ongoing business operations and regulatory compliance.
- 6The exact financial performance and key business developments require access to the full 10-Q document.
- 7This filing is part of the historical record for Pfizer's performance in the mid-1990s.
Frequently Asked Questions
This 10-Q filing provides a quarterly update on Pfizer Inc.'s financial condition and operational results for the period ending March 30, 1996. It allows investors and the public to track the company's performance between annual reports.
A 10-Q filing typically includes unaudited financial statements (income statement, balance sheet, cash flow statement), management's discussion and analysis of financial condition and results of operations, and disclosures on legal proceedings or significant business events. Specifics would be detailed within the full document.
This quarterly report offers a snapshot of Pfizer's performance during the first quarter of 1996. To assess overall financial health, investors should review this filing in conjunction with other quarterly reports, the annual report for 1996, and potentially historical filings to understand trends and long-term performance.
The provided text is a directory listing of the filing on the SEC's EDGAR system. To access the detailed financial statements, management's discussion, and other crucial information, you would need to locate and download the full 10-Q document (likely the .txt or HTML version) from the SEC's EDGAR database or a financial data provider.